Nanomedicine progress in thrombolytic therapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cardiovascular Medicine

Background:

• Thrombotic occlusions cause life-threatening conditions like heart attack and stroke.
• Current Plasminogen Activator (PA) therapy has limitations including short duration and bleeding risks.
• Nanomedicine offers a promising strategy to overcome these limitations in thrombolytic treatment.

Purpose of the Study:

• To review the pathophysiology of arterial and venous thrombosis.
• To summarize approved Plasminogen Activators (PA) and current nanomedicine research for targeted thrombolysis.
• To discuss strategies for designing nanocarriers for effective PA delivery and encapsulation.

Main Methods:

• Review of scientific literature on thrombosis, thrombolytic agents, and nanomedicine.
• Analysis of preclinical and clinical studies on nanocarrier-based PA delivery.
• Examination of ultrasound-assisted sonothrombolysis and nanocarrier-biological interactions.

Main Results:

• Nanomedicine-based vectorization of PA protects against degradation and improves therapeutic efficacy.
• Targeted nanocarriers facilitate site-specific delivery of PA, enhancing thrombolysis.
• Ultrasound-assisted methods show potential for improving thrombolysis in clinical settings.

Conclusions:

• Nanomedicine provides a valuable approach for precise treatment of acute thrombotic pathologies.
• Targeted nanocarriers and rational design are key for effective PA delivery.
• Further research into nanocarrier-biological interactions will optimize future therapies.